Clinical TrialsSome of the data were encouraging, including strong effects on sorbitol reduction and on a patient-reported outcome, the CMT-Health Index (CMT-HI), especially since these effects were maintained through 24 months.
Regulatory EngagementAPLT believes they are positioned for forward momentum as they engage with the FDA to discuss the latest data generated in sorbitol dehydrogenase (SORD) deficiency.
Strategic PartnershipsThe company entered an outlicensing agreement with Biossil, Inc. for AT-001, its investigational aldose reductase inhibitor (ARI) for diabetic cardiomyopathy (DbCM).